Leniolisib (1) – Joenja®
Activated phosphoinositide-3-kinase delta syndrome, aged ≥ 12 years, weighing ≥ 45 kg
Characteristics
| Start date | 01.07.2026 |
|---|---|
| Resolution | 17.12.2026 – active procedure |
| INN | Leniolisib |
| Brand name | Joenja® |
| Pharm. company | Pharming Group BV |
| G-BA Procedure ID | D-1350 |
| Therapeutic area | Hematopoietic diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions